Medtech Leader Erica Rogers Joins Ceribell Board of Directors
Ceribell (NASDAQ: CBLL), a medical technology company specializing in neurological diagnostics, has appointed Erica Rogers to its Board of Directors. Rogers brings over 30 years of experience in leading medical device companies, most notably as CEO of Silk Road Medical, where she grew the company from a 25-person startup to a 500-employee public company with $175 million in revenue.
Under Rogers' leadership, Silk Road Medical achieved FDA approval and commercial expansion, ultimately leading to its acquisition by Boston Scientific Corporation. Her appointment comes as Ceribell expands its point-of-care EEG system, which is currently used in over 550 hospitals to improve care for critically ill patients.
Ceribell (NASDAQ: CBLL), un'azienda di tecnologia medica specializzata in diagnostica neurologica, ha nominato Erica Rogers nel Consiglio di Amministrazione. Rogers porta oltre 30 anni di esperienza nel settore delle aziende leader di dispositivi medici, in particolare come CEO di Silk Road Medical, dove ha guidato l'azienda da una startup di 25 dipendenti a una società pubblica di 500 dipendenti con un fatturato di 175 milioni di dollari.
sotto la guida di Rogers, Silk Road Medical ha ottenuto l'approvazione FDA e un'espansione commerciale, culminata nell'acquisizione da parte della Boston Scientific Corporation.La sua nomina arriva mentre Ceribell amplia il proprio sistema EEG point-of-care, attualmente utilizzato in oltre 550 ospedali per migliorare l'assistenza ai pazienti in condizioni critiche.
Ceribell (NASDAQ: CBLL), una empresa de tecnología médica especializada en diagnóstico neurológico, ha nombrado a Erica Rogers como miembro de su Junta Directiva. Rogers aporta más de 30 años de experiencia en empresas líderes de dispositivos médicos, destacadamente como CEO de Silk Road Medical, donde llevó la empresa de una startup de 25 personas a una compañía pública de 500 empleados con ingresos de 175 millones de dólares.
Bajo la dirección de Rogers, Silk Road Medical obtuvo la aprobación de la FDA y una expansión comercial, que finalmente condujo a su adquisición por parte de Boston Scientific Corporation. Su nombramiento llega en un momento en que Ceribell amplía su sistema EEG de punto de atención, que actualmente se utiliza en más de 550 hospitales para mejorar la atención a pacientes críticamente enfermos.
Ceribell (나스닥: CBLL)은 신경 진단에 특화된 의료기술 회사로, Erica Rogers를 이사회에 임명했습니다. Rogers는 의료기기 선도 기업들을 이끄는 데 30년이 넘는 경력을 보유하고 있으며, 특히 Silk Road Medical의 CEO로서 회사를 25명의 스타트업에서 500명의 직원이 있는 상장기업으로 성장시켜 매출 1억7500만 달러를 달성했습니다.
Rogers의 리더십 아래 Silk Road Medical은 FDA 승인을 받고 상업적 확장을 이루었으며, 결국 Boston Scientific Corporation에 인수되었습니다. 그녀의 임명은 Ceribell이 현재 중환자 치료를 개선하기 위해 전 세계 550개 이상의 병원에서 사용되는 현장형 EEG 시스템을 확장하는 시점에 발표되었습니다.
Ceribell (NASDAQ: CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic neurologique, a nommé Erica Rogers au conseil d'administration. Rogers apporte plus de 30 ans d'expérience dans des entreprises leaders de dispositifs médicaux, notamment en tant queCEO de Silk Road Medical, où elle a fait passer l'entreprise d'une startup de 25 personnes à une société publique de 500 employés avec un chiffre d'affaires de 175 millions de dollars.
Sous la direction de Rogers, Silk Road Medical a obtenu l'approbation de la FDA et une expansion commerciale, menant finalement à son acquisition par Boston Scientific Corporation. Sa nomination intervient alors que Ceribell étend son système EEG au point de care, actuellement utilisé dans plus de 550 hôpitaux pour améliorer les soins des patients gravement malades.
Ceribell (NASDAQ: CBLL), ein Medizintechnikunternehmen, das sich auf neurologische Diagnostik spezialisiert hat, hat Erica Rogers in den Vorstand berufen. Rogers bringt über 30 Jahre Erfahrung in führenden Herstellern von Medizinprodukten mit, insbesondere als CEO von Silk Road Medical, wo sie das Unternehmen von einem 25-köpfigen Startup zu einem börsennotierten Unternehmen mit 500 Mitarbeitern und einem Umsatz von 175 Millionen US-Dollar geführt hat.
Unter Rogers' Führung erreichte Silk Road Medical die FDA-Zulassung und ein kommerzielles Wachstum, was letztlich zur Übernahme durch Boston Scientific Corporation führte. Ihre Berufung erfolgt, während Ceribell sein Point-of-Care-EEG-System ausweitet, das derzeit in über 550 Krankenhäusern eingesetzt wird, um die Versorgung kritisch kranker Patienten zu verbessern.
Ceribell (NASDAQ: CBLL)، شركة تكنولوجيا طبية متخصصة في التشخيص العصبي، عينت Erica Rogers في مجلس إدارتها. تتمتع Rogers بخبرة تزيد عن 30 عامًا في شركات الأجهزة الطبية الرائدة، لا سيما كالرئيسة التنفيذية لـ Silk Road Medical، حيث قادت الشركة من شركة ناشئة تضم 25 موظفًا إلى شركة عامة بـ 500 موظف وبإيرادات قدرها 175 مليون دولار.
تحت قيادة Rogers، حققت Silk Road Medical موافقة إدارة الغذاء والدواء (FDA) وتوسعًا تجاريًا، وفي نهاية المطاف أدى ذلك إلى استحواذها من قِبل Boston Scientific Corporation. تأتي تعيينها في وقت توسع Ceribell نظام EEG في نقطة الرعاية، الذي يُستخدم حاليًا في أكثر من 550 مستشفى لتحسين رعاية المرضى في الحالات الحرجة.
Ceribell（纳斯达克代码：CBLL），一家专注于神经诊断的医疗科技公司，已任命 Erica Rogers 加入董事会。Rogers 拥有在领先医疗器械公司超过 30 年的经验，尤其担任 Silk Road Medical 的首席执行官时，将公司从 25 名员工的初创企业发展为拥有 500 名员工、年收入 1.75 亿美元 的上市公司。
在 Rogers 的领导下，Silk Road Medical 获得了 FDA 批准并实现了商业扩张，最终被 Boston Scientific Corporation 收购。她的任命恰逢 Ceribell 扩大其现场床旁 EEG 系统之际，该系统目前已在 超过 550 家医院 使用，以改善危重病人的护理。
- Appointment of highly experienced medtech executive with proven track record of scaling healthcare companies
- New director has successfully led previous company from startup to $175M revenue and acquisition
- Current market penetration in over 550 hospitals demonstrates strong product adoption
- Strategic addition to board during company's growth phase
- None.
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell’s Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting.
Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently served as Chief Executive Officer of Silk Road Medical, Inc. and has held Board positions with HistoSonics, Axena Health, Sight Sciences, LightForce, and Medicines360. At Silk Road, Rogers led the business from its early stages through FDA approval and broad commercial expansion, which ultimately resulted in acquisition by Boston Scientific Corporation. Under her leadership, the organization grew significantly from a 25-person startup to a 500-employee, publicly-traded company with revenue exceeding
“We welcome Erica at a pivotal growth phase for Ceribell, as we expand nationwide access to our point-of-care EEG system to help clinicians deliver timely care for critically ill patients,” said Jane Chao, PhD, Co-founder and Chief Executive Officer of Ceribell. “Her experience in scaling healthcare companies and driving adoption of new technologies in clinical practice will be invaluable as we work to establish the Ceribell System as the standard of care.”
“Ceribell is pioneering a new era of timely brain monitoring, positively transforming patient outcomes,” said Erica Rogers. “The impact of its groundbreaking rapid EEG technology has already improved care for hundreds of thousands of critically ill patients in more than 550 hospitals. I look forward to supporting its ongoing efforts to broaden access to this significant advancement in healthcare.”
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other statements that are not statements of historical fact. Forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope,” and other words of similar meaning. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties are described under the “Risk Factors” sections of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings are available on the SEC’s website at https://sec.gov/ and on Ceribell’s website at https://investors.ceribell.com/. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow Ceribell on LinkedIn.
Investor Contacts
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
Who is Erica Rogers and why did Ceribell (CBLL) appoint her to the board?
What is Ceribell's (CBLL) current market presence in hospitals?
What was Erica Rogers' track record at Silk Road Medical?
What is Ceribell's (CBLL) main business focus?
What other board experience does Erica Rogers bring to Ceribell (CBLL)?
